ClinicalTrials.gg
CompletedNCT00400179Updated Sep 19, 2024Results posted

A Safety and Efficacy Study in Patients With Gastric Cancer

A Phase 3 interventional study of S-1/Cisplatin and 5-FU/cisplatin in Gastric Cancer, sponsored by Taiho Oncology, Inc.. Completed at 33 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-09-19.

Sponsored by Taiho Oncology, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,053
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 65 studies testing tegafur in Stomach Neoplasms — 10 open to participants now, 11 under way, 1 of them phase 3. Tegafur · Stomach Neoplasms.

Enrollment
Largest of 64
1,053 · median 62
Started
2005
with 2 others
Phase 3
13 of 65
1 open now
Registered
1st of 65
by date
Lead sponsor
2 of 65
Taiho Oncology, Inc.

Among the 65 studies testing tegafur in Stomach Neoplasms, this one has the largest enrollment of the 64 interventional ones that give a count, is one of 3 that started in 2005, is one of 13 in phase 3, and was the 1st registered.

Stomach Neoplasms

3,403 studies on the registry are indexed under Stomach Neoplasms; 995 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

10 of the 65 studies testing tegafur in Stomach Neoplasms are open now, in 3 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 10 open studies →

About tegafur

Tegafur: first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 376 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 69 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 65 studies testing tegafur in Stomach Neoplasms, or all of them as a file.
02

Study summary

This is an open-label, international, two-arm, parallel, randomized, Phase 3 study evaluating the efficacy and safety of S-1/cisplatin versus 5-FU/cisplatin in patients with advanced gastric cancer previously untreated with chemotherapy for advanced disease. Patients will be randomly assigned (1:1) to S-1/cisplatin (experimental arm) or 5-FU/cisplatin (control arm). Patients will be stratified by number of metastatic sites (one vs. more than one), locally advanced or metastatic disease, prior adjuvant therapy (yes or no), measurable or non-measurable disease, and center.

03

Conditions studied

  • Gastric Cancer

Browse trials for

Keywords

  • Gastric Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

A patient must meet all of the following inclusion criteria to be eligible for enrollment in this study:

  • Has given written
  • Has confirmed, unresectable, locally advanced (Stage IV) or gastric cancer, including adenocarcinoma of the gastro-esophageal junction
  • Has measurable or evaluable but non-, defined as follows:

    • Measurable Disease - Patients with measurable disease as defined by criteria, i.e., the presence of at least one measurable lesion. A measurable lesion is one that can be accurately measured in at least one dimension with the longest diameter >_ 20 mm using conventional techniques or >_ 10 mm using spiral Computed Tomography (CT)scan. Locally recurrent disease (other than primary) is accepted if there is at least one measurable lesion (i.e. peritoneal mass, lymph node, etc.)
    • Evaluable but Non-measurable Disease - Patients with all lesions below the limits defined above for measureable disease (i.e., longest diameter \< 20 mm with conventional techniques or \< 10 mm with spiral CT) excluding those patients with only a primary lesion and/or with only non-evaluable cancer such as bone metastases, ascites, pleural or pericardia effusions, lymphangitic carcinomatosis of the skin or lung, previously irradiated lesions not in progression, or peritoneal carcinomatosis \< 10 mm in diameter with conventional imaging techniques.
  • No prior palliative chemotherapy is permitted. and /or neo-adjuvant chemotherapy is permitted if more than 12 months have elapsed between the end of adjuvant or neo-adjuvant therapy and first recurrence. This does not qualify as therapy.
  • Is able to take medications orally
  • Is >_ 18 years of age
  • Is at least 3 weeks from prior major surgery
  • Is at least 4 weeks from prior radiotherapy
  • Has a performance status 0 to 1
  • Has adequate organ function as defined by the following criteria:

    • (SGOT) and ALT (SGPT) \<_ 2.5 x ; if liver function abnormalities are due to underlying liver metastasis, AST (SGOT) and ALT (SGPT) \<_ 5 x ULN
    • Total serum of \<_ 1.5 x ULN
    • Absolute granulocyte count of >_ 1,500/mm (i.e. >_ 1.5 x 10/L by International Units (IU)
    • count >_ 100,000/mm (IU: >_ 100 x 10/L
    • value of >_ 9.0 g/dL
    • Calculated >_ 60 mL/min (Cockcroft-Gault formula)
  • Is willing and able to comply with scheduled visits, treatment plans, laboratory tests and other study procedures

Exclusion criteria

Exclusion Criteria:

Exclude a patient from this study if he/she does not fulfill the inclusion criteria, or if any of the following conditions are observed:

  • Has had a treatment with any of the following within the specified timeframe prior to study drug administration:

    • Any prior palliative chemotherapy or any previous therapy for , including any chemotherapy, immunotherapy, biologic or hormonal therapy, within the past 5 years.
    • or neo-adjuvant therapy within the past 12 months
    • Concurrent treatment with any anti-cancer agent
    • Prior cisplatin as neo-adjuvant and /or adjuvant chemotherapy with cumulative dose > 300 mg/m
    • > 25% of marrow-bearing bone radiated
    • Concurrent treatment with an investigational agent or within 30 days from randomization
    • Concurrent enrollment in another clinical study
  • Has a serious illness or medical condition(s) including, but not limited to the following:

    • Known brain or
    • Uncontrolled ascites requiring drainage at least twice a week
    • Other malignancies within the past 5 years, except adequately treated carcinoma-in-situ of the cervix or non-melanoma skin cancer
    • Myocardial infarction within the last 6 months, severe/unstable angina, congestive heart failure (NYHA) class III or IV
    • Chronic nausea, vomiting or diarrhea
    • Known (HIV) or acquired immunodeficiency syndrome (AIDS-related illness
    • Psychiatric disorder that may interfere with consent and/or protocol compliance
    • Known neuropathy, Grade 2 or higher
    • Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, and in the judgement of the Investigator would make the patient inappropriate for entry into this study
  • Is receiving concomitant treatment with drugs interacting with S-1. The following drugs are prohibited because there may be an interaction with S-1:

    • Sorivudine, uracil, cimetidine, folinic acid, and dipyridamole (may enhance S-1 activity)
    • Allopurinol (may diminish S-1 activity
    • Phenytoin (S-1 may enhance phenytoin activity)
    • Flucytosine, a fluorinated pyrimidine antifungal agent (may enhance S-1 activity)
  • Is receiving concomitant treatment with drugs interacting with 5-FU:

    • Sorivudine, uracil, cimetidine, folinic acid, and dipyridamole(may enhance 5-FU activity)
    • Allopurinol (may diminish 5-FU activity)
    • Phenytoin (5-FU may enhance phenytoin activity)
  • Is receiving concomitant treatment with drugs interacting with cisplatin:

    • Phenytoin (cisplatin may diminish phenytoin activity)
    • Aminoglycosides (should be avoided within 8 days after cisplatin administration)
    • Ethyol (may diminish cisplatin activity
  • Is a pregnant or lactating female
  • Has known to 5-FU or cisplatin
  • Patients with who refuse to use an adequate means of (including male patients)
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,053 participants (actual)

Study arms

  • Active comparator
    A

    In Arm A, S-1 25 mg/m² was administered orally BID from Day 1 through Day 21 followed by a recovery period from Days 22 through Day 28. On Day 1, the morning dose of S-1 was administered before cisplatin 75 mg/m2 administration as a 1- to 3-hour IV infusion. This regimen was repeated every 4 weeks. S-1 was administered one hour before or one hour after a meal with a glass of water (approximately 100 mL).

    Drug: S-1/Cisplatin

  • Active comparator
    B

    In Arm B, 5-FU 1000 mg/m2/24 hours was administered by continuous intravenous infusion (CIV) over 120 hours (on Days 1 through 5). This regimen was repeated every 4 weeks. 5-FU CIV followed cisplatin infusion on Day 1. All 5-FU used in this study was commercially available product.

    Drug: 5-FU/cisplatin

Interventions

  • DrugS-1/Cisplatin

    Drug pages: Tegafur · Gimeracil · Oxonic Acid · Cisplatin

    In Arm A, S-1 25 mg/m2 was taken orally two times daily for 21 days followed by a 7-day recovery period. The patient was instructed to have nothing by mouth (NPO 1 hour prior to and 1 hour after S-1 administration. S-1 was taken with approximately 8 ounces of water and prior to cisplatin infusion on Day 1. Cisplatin 75 mg/m2 was administered as a 1- to 3-hour IV infusion after the morning dose of S-1 on Day 1 of each cycle. This regimen was repeated every 4 weeks with a maximum of 6 cycles of treatment for cisplatin.

  • Drug5-FU/cisplatin

    Drug pages: Fluorouracil · Cisplatin

    In Arm B, 5-FU 1000 mg/m2/24 hours was administered CIV on Days 1 through 5 following cisplatin 100 mg/m2 administered IV as a 1- to 3-hour infusion on Day 1. This regimen was repeated every 4 weeks with a maximum of 6 cycles of treatment for cisplatin.

06

What researchers measure

Primary outcomes

  1. Median Survival

    Survival was defined as the time from the date of randomization to the time of death (from any cause) for each patient.

    Time frame: The cutoff date for survival analysis was 07 March 2008 (12 months after last patient randomized).

Secondary outcomes

  1. Overall Response Rate (ORR)

    The proportion of patients with objective evidence of complete response (CR) or partial response (PR) based on tumor response assessments. Per the Response Evaluation Criteria in Solid tumors (RECIST), CR was defined as the disappearance of all target lesions for at least 4 weeks, and PR was defined as at least a 30% decrease in the sum of the longest diameter of target lesions.

    Time frame: Data cutoff was 07 March 2008 (12 months after last patient randomized).

  2. Duration of Response (DR)

    Duration of response was defined as the time from date of first confirmed response (CR or PR) to date of first progressive disease (PD) or death. Per the RECIST criteria, definitions were as follows: CR was the disappearance of all target lesions for at least 4 weeks, PR was at least a 30% decrease in the sum of the longest diameter of target lesions, and PD was at least a 20% increase in the sum of the longest diameter of target lesions.

    Time frame: Data cutoff was 07 March 2008 (12 months after last patient was randomized).

  3. Progression-free Survival (PFS)

    The time from randomization to date of first documented PD or date of death, whichever occurred first.

    Time frame: From date of randomization until date of first documented PD, date of death, or until data cutoff on 07 March 2008 (12 months after last patient randomized), whichever came first.

  4. Time to Treatment Failure (TTF)

    The time from randomization to date of permanent discontinuation of S-1 or 5-FU, first documented PD, or death, whichever occurred first.

    Time frame: From date of randomization until date of permanent discontinuation of S-1 or 5-FU, first documented PD, death, or data cutoff on 07 March 2008 (12 months after last patient randomized), whichever came first.

07

Results

Posted Apr 23, 2012

Participant flow

This multicenter study was conducted between May 18, 2005 and March 7, 2008 in 24 countries including the United States. Study centers were also located in Canada, Eastern and Western Europe, South America, Australia, and ex-Soviet Union block of nations.

Participant flow — Overall Study
MilestoneS-1/Cisplatin5-FU/Cisplatin
Started527526
Completed521508
Not completed618
Withdrew: Adverse event22
Withdrew: Death12
Withdrew: Withdrew consent15
Withdrew: Disease progression11
Withdrew: Intercurrent illness01
Withdrew: Investigator judgment01
Withdrew: Randomization error/patient ineligible16

Outcome measures

SecondaryOverall Response Rate (ORR)

The proportion of patients with objective evidence of complete response (CR) or partial response (PR) based on tumor response assessments. Per the Response Evaluation Criteria in Solid tumors (RECIST), CR was defined as the disappearance of all target lesions for at least 4 weeks, and PR was defined as at least a 30% decrease in the sum of the longest diameter of target lesions.

Time frame:
Data cutoff was 07 March 2008 (12 months after last patient randomized).
Reported as:
Number · Percentage of patients in each group
Overall Response Rate (ORR)
Percentage of patients in each groupS-1/Cisplatin5-FU/Cisplatin
Overall Response Rate (ORR)29.1 (24.7 to 33.8)31.9 (27.3 to 36.9)
Statistical analysis
  • S-1/Cisplatin vs 5-FU/Cisplatin · Fisher Exact · p = 0.3952
SecondaryDuration of Response (DR)

Duration of response was defined as the time from date of first confirmed response (CR or PR) to date of first progressive disease (PD) or death. Per the RECIST criteria, definitions were as follows: CR was the disappearance of all target lesions for at least 4 weeks, PR was at least a 30% decrease in the sum of the longest diameter of target lesions, and PD was at least a 20% increase in the sum of the longest diameter of target lesions.

Time frame:
Data cutoff was 07 March 2008 (12 months after last patient was randomized).
Reported as:
Median · Months
Duration of Response (DR)
MonthsS-1/Cisplatin5-FU/Cisplatin
Duration of Response (DR)6.5 (5.8 to 7.4)5.8 (5.5 to 6.1)
Statistical analysis
  • S-1/Cisplatin vs 5-FU/Cisplatin · Log Rank · p = 0.0808 · Hazard ratio (hr): 0.77 · 95% CI 0.57 to 1.03
SecondaryProgression-free Survival (PFS)

The time from randomization to date of first documented PD or date of death, whichever occurred first.

Time frame:
From date of randomization until date of first documented PD, date of death, or until data cutoff on 07 March 2008 (12 months after last patient randomized), whichever came first.
Reported as:
Median · Months
Progression-free Survival (PFS)
MonthsS-1/Cisplatin5-FU/Cisplatin
Progression-free Survival (PFS)4.8 (4.0 to 5.5)5.5 (4.4 to 5.8)
Statistical analysis
  • S-1/Cisplatin vs 5-FU/Cisplatin · Log Rank · p = 0.9158 · Hazard ratio (hr): 0.99 · 95% CI 0.86 to 1.14
SecondaryTime to Treatment Failure (TTF)

The time from randomization to date of permanent discontinuation of S-1 or 5-FU, first documented PD, or death, whichever occurred first.

Time frame:
From date of randomization until date of permanent discontinuation of S-1 or 5-FU, first documented PD, death, or data cutoff on 07 March 2008 (12 months after last patient randomized), whichever came first.
Reported as:
Median · Months
Time to Treatment Failure (TTF)
MonthsS-1/Cisplatin5-FU/Cisplatin
Time to Treatment Failure (TTF)3.8 (3.7 to 4.0)3.8 (3.7 to 4.4)
Statistical analysis
  • S-1/Cisplatin vs 5-FU/Cisplatin · Log Rank · p = 0.0320 · Hazard ratio (hr): 0.87 · 95% CI 0.77 to 0.99
PrimaryMedian Survival

Survival was defined as the time from the date of randomization to the time of death (from any cause) for each patient.

Time frame:
The cutoff date for survival analysis was 07 March 2008 (12 months after last patient randomized).
Reported as:
Median · Months
Median Survival
MonthsS-1/Cisplatin5-FU/Cisplatin
Median Survival8.6 (7.9 to 9.5)7.9 (7.2 to 8.5)
Statistical analysis
  • S-1/Cisplatin vs 5-FU/Cisplatin · Log Rank · p = 0.1983 · Hazard ratio (hr): 0.92 · 95% CI 0.80 to 1.05

Adverse events

Collected over From the start of study drug administration until 12 months after last patient randomized. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
S-1/Cisplatin—257/521 (49.3%)514/521 (98.7%)
5-FU/Cisplatin—248/508 (48.8%)504/508 (99.2%)
Most frequent serious events
Showing 10 of 258
Most frequent serious events
EventS-1/Cisplatin5-FU/Cisplatin
Disease progressionGeneral disorders53/52134/508
AnaemiaBlood and lymphatic system disorders33/52131/508
DehydrationMetabolism and nutrition disorders21/52132/508
Febrile neutropeniaBlood and lymphatic system disorders8/52131/508
NeutropeniaBlood and lymphatic system disorders8/52131/508
StomatitisGastrointestinal disorders3/52124/508
VomitingGastrointestinal disorders23/52117/508
ThrombocytopeniaBlood and lymphatic system disorders11/52117/508
Deep vein thrombosisVascular disorders5/52117/508
NauseaGastrointestinal disorders17/52110/508
Most frequent other events
Showing 10 of 89
Most frequent other events
EventS-1/Cisplatin5-FU/Cisplatin
NauseaGastrointestinal disorders321/521342/508
VomitingGastrointestinal disorders260/521281/508
NeutropeniaBlood and lymphatic system disorders149/521240/508
AnaemiaBlood and lymphatic system disorders229/521234/508
FatigueGeneral disorders205/521200/508
DiarrhoeaGastrointestinal disorders152/521195/508
AnorexiaMetabolism and nutrition disorders164/521177/508
Weight decreasedInvestigations148/521164/508
StomatitisGastrointestinal disorders33/521153/508
Mucosal inflammationGeneral disorders20/521152/508

Baseline characteristics

Age, Continuous
Age, Continuous(Years)S-1/Cisplatin5-FU/CisplatinTotal
Baseline Measure Data (descriptive stats, median)59.0 (18 to 83)59.0 (18 to 85)59.0 (18 to 85)
Sex: Female, Male
Sex: Female, Male(Participants)S-1/Cisplatin5-FU/CisplatinTotal
Female139161300
Male382347729
Race (NIH/OMB)
Race (NIH/OMB)(Participants)S-1/Cisplatin5-FU/CisplatinTotal
American Indian or Alaska Native4610
Asian448
Native Hawaiian or Other Pacific Islander000
Black or African American5712
White447438885
More than one race000
Unknown or Not Reported6153114
Body surface area (BSA) Categories
Body surface area (BSA) Categories(Participants)S-1/Cisplatin5-FU/CisplatinTotal
</=1.29 m2459
1.30-1.49 m2464490
1.50-1.69 m2118147265
1.70-1.89 m2208181389
1.90-2.09 m211493207
2.10-2.29 m2293463
>/=2.30 m2246
Eastern Cooperative Oncology Group (ECOG) Performance Status
Eastern Cooperative Oncology Group (ECOG) Performance Status(Participants)S-1/Cisplatin5-FU/CisplatinTotal
0226200426
1295308603
Tissue Type
Tissue Type(Participants)S-1/Cisplatin5-FU/CisplatinTotal
Papillary adenocarcinoma151530
Tubular adenocarcinoma132113245
Well-differentiated201737
Moderately-differentiated10591196
Unknown7512
Poorly differentiated adenocarcinoma210189399
Signet-ring cell carcinoma7595170
Mucinous adenocarcinoma283260
Other9794191
Adenocarcinoma NOS8787174
Poorly differentiated cancer729
Unknown/not specified112
Other types246
Anatomical Location of Primary Lesion
Anatomical Location of Primary Lesion(Participants)S-1/Cisplatin5-FU/CisplatinTotal
Stomach438417855
Gastroesophageal junction8288170
Stomach and gastroesophageal junction134
Extent of Disease
Extent of Disease(Participants)S-1/Cisplatin5-FU/CisplatinTotal
Locally advanced232043
1 metastatic site157161318
>/=2 metastatic sites340327667
Not assessed101

1 further baseline measures are reported on the registry.

08

Study locations

33 sites
  • Clearview Cancer Center
    Huntsville, Alabama 35801, United States
  • Saint Joseph Medical Center
    Burbank, California 91505, United States
  • Dr. Ronald Yanagihara
    Gilroy, California 95020, United States
  • Norris Cancer Center
    Los Angeles, California 90033, United States
  • Comprehensive Cancer Center
    Palm Springs, California 92262, United States
  • Saint Francis Memorial Hospital
    San Francisco, California 94109, United States
  • Premiere Oncology
    Santa Monica, California 90404, United States
  • Western Hematology/Oncology
    Lakewood, Colorado 80215, United States
  • Broward Oncology Associates
    Fort Lauderdale, Florida 33308, United States
  • Alexandar Rosemurgy
    Tampa, Florida 33606, United States
  • Palm Beach Cancer Institute
    West Palm Beach, Florida 33401, United States
  • Straub Clinic and Hospital
    Honolulu, Hawaii 96813, United States
  • Robert H. Lurie Comprehensive Cancer Center
    Chicago, Illinois 60611, United States
  • University of Chicago Medical Center
    Chicago, Illinois 60637-1470, United States
  • Oncology and Hematology
    Metairie, Louisiana 70006, United States
  • St. Lukes Cancer Care Center
    Duluth, Minnesota 55802, United States
  • Neuroscience Center
    Saint Louis, Missouri 63110, United States
  • St. Louis University Cancer Center
    Saint Louis, Missouri 63110, United States
  • Southern Nevada Cancer Research Foundation
    Las Vegas, Nevada 89106, United States
  • AHS Lovelace Medical Group,LLC
    Albuquerque, New Mexico 87102, United States
  • New Mexico Cancer Center Associates
    Albuquerque, New Mexico 87106, United States
  • University of New Mexico
    Albuquerque, New Mexico 87106, United States
  • Hoo Chun, MD
    Hawthorne, New York 10532, United States
  • Hematology/Oncology Associates of Rockland
    New City, New York 10956, United States
  • New Bern Cancer Care
    New Bern, North Carolina 28560, United States
  • Abramson Cancer Center
    Philadelphia, Pennsylvania 19104, United States
  • Thomas Jefferson University
    Philadelphia, Pennsylvania 19107, United States
  • Charleston Cancer Center
    Charleston, South Carolina 29406, United States
  • Associates in Oncology and Hematology
    Chattanooga, Tennessee 37404, United States
  • Lexington Oncology Associates
    Chattanooga, Tennessee 37404, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • University of Wisconsin Comprehensive Cancer Center
    Madison, Wisconsin 53792, United States
  • CHUM Hopital Saint-Luc
    Montreal, Quebec H2X3J4, Canada
09

References and documents

Publications

  • Bodoky G, Scheulen ME, Rivera F, Jassem J, Carrato A, Moiseyenko V, Vynnychenko I, Prausova J, Van Laethem JL, Cascinu S, Ajani JA. Clinical Benefit and Health-Related Quality of Life Assessment in Patients Treated with Cisplatin/S-1 Versus Cisplatin/5-FU: Secondary End Point Results From the First-Line Advanced Gastric Cancer Study (FLAGS). J Gastrointest Cancer. 2015 Jun;46(2):109-17. doi: 10.1007/s12029-014-9680-1. PubMed 25707610 ↗
  • Ajani JA, Buyse M, Lichinitser M, Gorbunova V, Bodoky G, Douillard JY, Cascinu S, Heinemann V, Zaucha R, Carrato A, Ferry D, Moiseyenko V. Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: Results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer Study. Eur J Cancer. 2013 Nov;49(17):3616-24. doi: 10.1016/j.ejca.2013.07.003. Epub 2013 Jul 27. PubMed 23899532 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2005, a primary completion of Mar 2008 and a completion of Apr 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2012, 4 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2005
First posted
Nov 16, 2006
Start
May 2005
Primary completionActual
Mar 2008
CompletionActual
Apr 2008
Results first posted
Apr 23, 2012
Last update
Sep 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00400179
Collaborators
Quintiles, Inc.
Responsible party
Sponsor
First posted
Nov 16, 2006
Start date
May 2005
Primary completion
Mar 2008
Completion
Apr 2008
Results posted
Apr 23, 2012
Last update
Sep 19, 2024

Study contacts

Fabio Benedetti, MD
study director · Taiho Oncology, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tegafur · Gimeracil · Oxonic Acid · Cisplatin · Fluorouracil

Start the discussion